Novo Nordisk hopes to begin approval process of once-weekly insulin in H1 2023
Another round of positive study data for insulin icodec has cemented the company’s belief that a global approval process can be initiated at the start of next year, Novo Nordisk executive Martin Holst Lange tells MedWatch.
by christopher due karlsson, translated by daniel pedersen
If everything pans out for Novo Nordisk in the near future, Denmark’s biggest pharmaceutical company expects to initiate a global application process for once-weekly insulin icodec in the first half of 2023, Executive Vice President for Development at Novo Nordisk Martin Holst Lange tells MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk has twin successes with once-weekly insulin
For subscribers
